Mazyar Shadman, MD, MPH

home / authors / mazyar-shadman-md-mph

Articles

Future Directions and Key Insights in LBCL Treatment

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

March 21st 2025

Experts discuss future directions and key insights in treating large B-cell lymphoma (LBCL).

Safety Management and Monitoring Protocols for Liso-cel

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

March 21st 2025

Experts discuss safety management and monitoring protocols for liso-cel in treating relapsed/refractory large B-cell lymphoma.

TRANSFORM Safety Summary

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

March 21st 2025

Experts provide a safety summary of the phase 3 TRANSFORM study, highlighting key safety findings for liso-cel in relapsed/refractory large B-cell lymphoma.

Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

March 14th 2025

Experts discuss clinical features and risk factors in navigating the decision between autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Impact of Manufacturing and Treatment Timing on Patient Outcomes for CAR T in R/R LBCL

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

March 14th 2025

Experts discuss the impact of manufacturing and treatment timing on patient outcomes for chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL).

Patient Selection and Timing Considerations for CAR T Therapy

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

March 7th 2025

Experts discuss patient selection and timing considerations for chimeric antigen receptor T-cell (CAR T) therapy in treating relapsed/refractory large B-cell lymphoma.

Long-Term Efficacy and Real-World Outcomes With Liso-cel

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

March 7th 2025

Experts discuss long-term efficacy and real-world outcomes with liso-cel in treating relapsed/refractory large B-cell lymphoma.

Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

February 28th 2025

Experts discuss the 3-year follow-up from the phase 3 TRANSFORM study, providing an overview of the study and key efficacy data.

Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS

February 28th 2025

Experts provide a brief overview of the current treatment landscape and unmet needs in relapsed/refractory (R/R) large B-cell lymphoma.